Swissmedic approves Moderna Switzerland GmbH coronavirus vaccine Spikevax XBB.1.5
22 September 2023 – Swissmedic's review of the data packages submitted found that the vaccine met the requirements for a COVID variant-adapted vaccine. It is administered as a single dose of 0.5 mL (50 micrograms per dose, dispersion for injection). The vaccine encodes the spike protein for Omicron subvariant XBB.1.5 of SARS-CoV-2. As with previous authorised coronavirus variant-adapted vaccines, no new safety signals have been detected.
For more information, see here.